Data gathered: May 29
Alternative Data for Grifols
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 295,000 | Sign up | Sign up | Sign up |
| Google Trends | 25 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 922 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Grifols
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.
| Price | $8.18 |
| Target Price | Sign up |
| Volume | 511,890 |
| Market Cap | $6.72B |
| Year Range | $6.49 - $9.55 |
| Dividend Yield | 0% |
| PE Ratio | 31.65 |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Contrasting Lexicon Pharmaceuticals (NASDAQ:LXRX) & Grifols (NASDAQ:GRFS)May 25 - ETF Daily News |
|
Credit Industriel ET Commercial Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)May 25 - ETF Daily News |
|
Grifols (NASDAQ:GRFS) Stock Rating Upgraded by Wall Street ZenMay 24 - ETF Daily News |
 |
Grifols: If This Works Out, It Has Massive UpsideMay 21 - SeekingAlpha |
United States Vaccines (Top 47) Market Research Report 2025-2033 Featuring Pharma Giants Such as Pfizer, Merck, Grifols, Sanofi Pasteur, AstraZeneca, GSK, Bavarian Nordic, Seqirus, DynavaxMay 21 - GlobeNewswire |
|
 |
Grifols (NASDAQ:GRFS) Rating Increased to Buy at StockNews.comMay 17 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 1.98B | 1.21B | 766M | 69M | 337M | 0.108 |
| Q3 '24 | 1.79B | 1.07B | 727M | 52M | 425M | 0.170 |
| Q2 '24 | 1.82B | 1.2B | 621M | 15M | 353M | 0.150 |
| Q1 '24 | 1.63B | 977M | 648M | 21M | 348M | 0.070 |
| Q4 '23 | 1.77B | 1.08B | 690M | 56M | 335M | 0.140 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Grifols (GRFS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Grifols?
The Market Cap of Grifols is $6.72B.
What is Grifols' PE Ratio?
As of today, Grifols' PE (Price to Earnings) ratio is 31.65.
What is the current stock price of Grifols?
Currently, the price of one share of Grifols stock is $8.18.
How can I analyze the GRFS stock price chart for investment decisions?
The GRFS stock price chart above provides a comprehensive visual representation of Grifols' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Grifols shares. Our platform offers an up-to-date GRFS stock price chart, along with technical data analysis and alternative data insights.
Does GRFS offer dividends to its shareholders?
As of our latest update, Grifols (GRFS) does not offer dividends to its shareholders. Investors interested in Grifols should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Grifols?
Some of the similar stocks of Grifols are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.